Artificial intelligence has quickly become embedded across the life sciences ecosystem. From target identification and clinical trial design, to manufacturing optimization and pharmacovigilance, AI systems are now capable of analyzing data at an unprecedented scale. Regulators are already responding. The FDA has emphasized that AI must function as a decision-support tool—not a replacement for scientific judgment.

This acceleration is transforming how organizations operate. But it is also introducing a new strategic challenge: one that has little to do with the algorithms themselves. As AI increases the speed and apparent precision of analysis, the limiting factor in high-stakes decision-making is no longer information. It is judgment.

In environments where decisions carry long-term regulatory, financial, and scientific consequences, experienced, real-time judgment becomes more important, not less.

AI Is Expanding, and Regulators Are Paying Attention

Regulators have already recognized the implications of AI’s growing role in drug development.

The FDA’s recently articulated Good AI Practice principles emphasize that artificial intelligence should function as a decision-support tool, not as a replacement for scientific or clinical judgment.

The agency’s framework stresses several key expectations:

• Clear context of use for AI systems
• Strong data governance and documentation
• Risk-based validation and oversight
• Continuous lifecycle monitoring
• Human oversight and accountability

In other words, regulators are not simply evaluating whether AI systems produce accurate outputs. They are evaluating whether organizations govern how those outputs are used.

This distinction is critical. In regulated environments, decisions influenced by AI may affect patient safety, product quality, and regulatory credibility. The responsibility for those decisions cannot be delegated to software. Human judgment remains central.

The Reality of Irreversible Decisions

In the life sciences, many of the most consequential decisions are effectively irreversible: A regulatory submission defines the evidentiary basis for a product approval. A pivotal trial design determines whether a therapy succeeds or fails. Manufacturing controls shape the long-term quality and scalability of a product. Commitments to specific technologies, vendors, or operational models can constrain an organization’s options for years.

Once made, these decisions cannot easily be undone without significant cost, disruption, or reputational risk.

Artificial intelligence can improve the analytical inputs into these decisions. It can surface patterns in complex datasets, model potential outcomes, and identify operational efficiencies.

But the presence of more analysis does not eliminate the need to interpret trade-offs.

In fact, it often makes those trade-offs harder to see.

A Hidden Risk: Automation Bias

One of the most subtle risks introduced by AI-enabled workflows is automation bias—the tendency for humans to place confidence in automated outputs.

Highly sophisticated models can produce predictions that appear authoritative. Performance metrics may suggest precision that exceeds the reliability of the underlying assumptions. An illusion of certainty can easily be created in this type of environment, and without human judgment and proper checks and balances, there is a real risk of AI producing hallucinatory outputs.

In reality, every AI system reflects choices made during its development:

• Which data were included
• How the model was trained
• What assumptions were embedded
• What limitations were accepted

These design decisions are rarely visible in the final output.

For organizations operating in regulated environments, the danger is not simply that a model might be wrong. The danger is that the organization may stop asking the questions that would reveal when the model should not be trusted.

This is why regulatory frameworks emphasize explainability, transparency, and multidisciplinary oversight. But these AI governance processes alone cannot replace experienced judgment operating in real time.

The Difference Between Analysis and Accountability 

Artificial intelligence excels at scaling analysis. It can rapidly synthesize information across datasets, identify patterns, and automate tasks that once required significant human effort.

But analysis and decision-making are not the same thing.

In high-stakes environments, decision quality depends on factors that algorithms are not designed to evaluate:

• Interpreting scientific nuance
• Weighing regulatory expectations
• Balancing operational feasibility
• Aligning stakeholders across organizations
• Assessing long-term strategic risk

These dimensions require context, experience, and cross-domain understanding. They also require accountability. No algorithm appears before regulators to defend a submission. No machine absorbs the reputational consequences of a flawed decision. Ultimately, the responsibility rests with human leadership.

AI can inform those decisions. It cannot own them.

Why Real-Time Judgment Matters

In practice, the most difficult decisions rarely occur under ideal conditions.

Teams face time pressure. Information is incomplete. Institutional knowledge may be fragmented across departments. Organizational incentives may discourage surfacing uncomfortable information. Under these circumstances, experienced judgment becomes particularly valuable.

Effective decision-making requires leaders who can:

• Synthesize information across scientific, operational, and regulatory domains
• Clarify which assumptions must hold true for a strategy to succeed
• Surface hidden risks before they become systemic failures
• Make trade-offs explicit before irreversible commitments are made

These capabilities are not purely analytical. They are interpretive and contextual, and require the ability to translate complexity into clear strategic choices.

The Emerging Competitive Advantage

As artificial intelligence becomes more accessible, analytical capabilities will increasingly converge across organizations.

Data processing will become faster. Predictive models will become more widely available. Automation will continue to reduce the cost of generating insights.

What will differentiate organizations is not their access to AI, but instead their ability to use it wisely.

Companies that integrate AI with experienced judgment—particularly in moments of high-impact decision-making—will be better positioned to navigate regulatory complexity, manage risk, and maintain scientific credibility. Those that rely on automated outputs without strong judgment frameworks may find themselves moving quickly, but not necessarily in the right direction.

AI Improves Speed. Judgment Protects Outcomes. 

Artificial intelligence is an extraordinary tool. Used responsibly, it has the potential to accelerate discovery, improve operational efficiency, and enhance decision-making across the life sciences industry.

But as AI expands, the importance of experienced judgment becomes more—not less—central.

In environments where decisions carry irreversible consequences, the question is not whether AI should be used.

The question is whether the people interpreting those outputs have the experience, context, and accountability to ensure that the right decisions are made.

Because in high-stakes environments, the difference is not more data. It is better judgment.

If your organization is integrating artificial intelligence into high-stakes scientific, regulatory, or operational decisions, the challenge is rarely the technology itself—it is ensuring the right judgment is applied at the right moment.

Contact Bracken to discuss how our judgment-led advisory can support your team.